These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

542 related articles for article (PubMed ID: 32683991)

  • 1. Emerging drugs for small cell lung cancer: a focused review on immune checkpoint inhibitors.
    Reddy HG; Qin A; Kalemkerian GP
    Expert Opin Emerg Drugs; 2020 Sep; 25(3):353-366. PubMed ID: 32683991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prolonging Survival: The Role of Immune Checkpoint Inhibitors in the Treatment of Extensive-Stage Small Cell Lung Cancer.
    Melosky B; Cheema PK; Brade A; McLeod D; Liu G; Price PW; Jao K; Schellenberg DD; Juergens R; Leighl N; Chu Q
    Oncologist; 2020 Nov; 25(11):981-992. PubMed ID: 32860288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The landscape of immune checkpoint inhibitor therapy in advanced lung cancer.
    Wang C; Li J; Zhang Q; Wu J; Xiao Y; Song L; Gong H; Li Y
    BMC Cancer; 2021 Aug; 21(1):968. PubMed ID: 34454455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current state of the art and future perspectives with immunotherapy in the management of small cell lung cancer.
    Rijavec E; Genova C; Biello F; Rossi G; Indini A; Grossi F
    Expert Rev Respir Med; 2021 Nov; 15(11):1427-1435. PubMed ID: 34590937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy for the treatment of metastatic small cell lung cancer: Focus on pembrolizumab.
    Koulouris A; Mountzios G
    Expert Rev Clin Pharmacol; 2021 Jun; 14(6):651-659. PubMed ID: 33902379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term survival in extensive-stage small-cell lung cancer treated with different immune checkpoint inhibitors in multiple-line therapies: A case report and literature review.
    Zhang X; Zheng J; Niu Y; Xue C; Yu Y; Tan K; Cui H
    Front Immunol; 2022; 13():1059331. PubMed ID: 36532013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of Immunotherapy in Extensive-Stage Small Cell Lung Cancer.
    Konala VM; Madhira BR; Ashraf S; Graziano S
    Oncology; 2020; 98(11):749-754. PubMed ID: 32663833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of Immune Checkpoint Inhibitors in Small Cell Lung Cancer.
    Cooper MR; Alrajhi AM; Durand CR
    Am J Ther; 2018; 25(3):e349-e356. PubMed ID: 29722737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer?
    Tanvetyanon T; Gray JE; Antonia SJ
    Expert Opin Biol Ther; 2017 Mar; 17(3):305-312. PubMed ID: 28064556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune checkpoint inhibitors: a new landscape for extensive stage small cell lung cancer treatment.
    Bianco A; D'Agnano V; Matera MG; Della Gravara L; Perrotta F; Rocco D
    Expert Rev Respir Med; 2021 Nov; 15(11):1415-1425. PubMed ID: 34374626
    [No Abstract]   [Full Text] [Related]  

  • 11. Continuous immunotherapy beyond progression in clinical practice for small cell lung cancer.
    Yamamoto K; Ninomaru T; Okada H; Hirano K; Shimada T; Hata A
    Thorac Cancer; 2024 May; 15(15):1271-1275. PubMed ID: 38623812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic Therapy of Extensive Stage Small Cell Lung Cancer in the Era of Immunotherapy.
    Ragavan M; Das M
    Curr Treat Options Oncol; 2020 Jun; 21(8):64. PubMed ID: 32601742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The evolving landscape of immunotherapy in small-cell lung cancer: A focus on predictive biomarkers.
    Gelsomino F; Lamberti G; Parisi C; Casolari L; Melotti B; Sperandi F; Ardizzoni A
    Cancer Treat Rev; 2019 Sep; 79():101887. PubMed ID: 31491661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Future of Immunotherapy in the Treatment of Small Cell Lung Cancer.
    Horn L; Reck M; Spigel DR
    Oncologist; 2016 Aug; 21(8):910-21. PubMed ID: 27354668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of immune checkpoint inhibitors (ICIs) in extensive-stage small cell lung cancer (SCLC).
    Ma X; Wang S; Zhang Y; Wei H; Yu J
    J Cancer Res Clin Oncol; 2021 Feb; 147(2):593-606. PubMed ID: 32852633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune checkpoint blockade in small cell lung cancer.
    Tay RY; Heigener D; Reck M; Califano R
    Lung Cancer; 2019 Nov; 137():31-37. PubMed ID: 31525648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of immunotherapy in small cell lung cancer.
    Calles A; Aguado G; Sandoval C; Álvarez R
    Clin Transl Oncol; 2019 Aug; 21(8):961-976. PubMed ID: 30637710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Role of Performance Status in Small-Cell Lung Cancer in the Era of Immune Checkpoint Inhibitors.
    Friedlaender A; Liu SV; Passaro A; Metro G; Banna G; Addeo A
    Clin Lung Cancer; 2020 Nov; 21(6):e539-e543. PubMed ID: 32499210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current and future therapeutic approaches for the treatment of small cell lung cancer.
    Rossi A; Tay R; Chiramel J; Prelaj A; Califano R
    Expert Rev Anticancer Ther; 2018 May; 18(5):473-486. PubMed ID: 29544351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy for small-cell lung cancer: emerging evidence.
    Reck M; Heigener D; Reinmuth N
    Future Oncol; 2016 Apr; 12(7):931-43. PubMed ID: 26882955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.